The creation and progression of multiple sclerosis present scientists with many riddles. Now researchers from the universities of Würzburg and Amsterdam have succeeded in resolving an apparent contradiction in the findings to date. Their work will contribute to a better understanding of the impact of treatments at the so-called blood-brain barrier.
Over two million people worldwide suffer from multiple sclerosis (MS), an initially usually relapsing chronic inflammatory autoimmune disease of the brain and spinal cord. A key element of the progression of the disease is the disruption of the so-called blood-brain barrier. The main component of this barrier are highly specialized cells that line the vascular walls from inside like wallpaper – these are known as endothelial cells. Using surface molecules and transmitters, they control the exodus of immune cells from the bloodstream to the brain tissue with great precision. During an acute flare-up with multiple sclerosis, the endothelial cells increasingly produce different signal molecules, which results in a mass exodus of immune cells to the brain tissue and leads to the characteristic damage.
Two molecules of central significance
Two molecules play important roles in the communication between endothelial and immune cells: The vascular cell adhesion molecule 1, or VCAM-1 for short, sits on the surface of the endothelial cells and serves as a docking point for the receptor of the immune cells, integrin alpha 4 beta 1. Both therefore make good targets for potential drugs. And, in fact, using medicines to block the integrin on the immune cells prevents these from continuing to migrate from the blood to the brain tissue. This is the main action mechanism of the highly effective MS drug Natalizumab.
However, the scientists have been puzzled by a series of contradictory findings that are known in connection with a special variant of VCAM-1. “This molecule can become detached from the cell’s surface under inflammatory conditions and can then be identified in a soluble form in blood,” explains private lecturer Dr. Mathias Buttmann. And in this form it has caused confusion to date.
An irresolvable contradiction
“On the one hand, some studies show that a high concentration of these dissolved molecules in the blood correlates with a high level of inflammatory activity at the blood-brain barrier,” says Buttmann. This suggests that the molecule itself might even disrupt the barrier function. On the other hand, studies on MS patients treated with an interferon beta medicine found precisely the opposite: The higher the concentrations were here, the more reduced the disease activity exhibited by the patients. “Until now, these findings have represented an irresolvable contradiction, and the possible function of the dissolved molecules at the blood-brain barrier has remained unclear,” says Buttmann.
Mathias Buttmann is a senior physician at the University of Würzburg’s Department of Neurology and head of the Neuroimmunological Outpatient Clinic there. Together with scientists from the University of Amsterdam he has now found a solution to the seeming contradiction. The scientists present their work in the current issue of the scientific journal Acta Neuropathologica.
The key results of the study
“We were able to show that not only immune cells but also the endothelial cells of the blood-brain barrier carry integrin alpha 4 beta 1 on their surface,” is how Buttmann summarizes the key finding of this work. And under inflammatory conditions the brain endothelial cells produced more of the molecule. If the endothelial cells were stimulated with the dissolved variant of VCAM-1, they developed a disturbance to their barrier function. If, however, they had been pre-treated with Natalizumab, the barrier function remained largely intact. “This meant we were able to prove that the dissolved VCAM-1 variant disrupts the barrier function of human brain endothelial cells via integrin alpha 4,” explains Dr. Axel Haarmann, member of Buttmann’s team and lead author of the now published study.
Deeper understanding of the mode of action of MS therapeutics
According to the scientists, these findings indicate that Natalizumab has a two-fold protective effect at the blood-brain barrier: Alongside the known immune cell blockade, it also likely acts in a directly protective manner on brain endothelial cells in that it prevents destabilization of the barrier function, which is probably what happens in untreated MS patients.
And what explanation can there be for the fact that in MS patients treated with interferon beta high levels of dissolved VCAM-1 go hand-in-hand with reduced disease activity? Mathias Buttmann has one ready: “It probably makes a difference whereabouts in the body the dissolved molecules are released.” If, as is the case in MS episodes, this happens in inflammatory areas of the brain, the disruption to the blood-brain barrier is intensified. “Under treatment with interferon beta, however, the molecules are probably mainly released close to the injection sites frequently altered by inflammatory activity,” says Buttmann. There they might block integrin receptors on immune cells and in so doing ultimately have a protective effect, only reaching the blood-brain barrier in a small concentration and therefore having no harmful effect there.
Haarmann A, Nowak E, Deiß A, van der Pol S, Monoranu C, Kooij G, Müller N, van der Valk P, Stoll G, de Vries HE, Berberich-Siebelt F, Buttmann M. Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin alpha-4-transduced outside-in signalling. Acta Neuropathologica, published online on March 27, 2015. DOI: 10.1007/s00401-015-1417-0
Dr. med. Mathias Buttmann, T: +49 (0)931 201-23777, e-mail: firstname.lastname@example.org
Gunnar Bartsch | idw - Informationsdienst Wissenschaft
Electrical 'switch' in brain's capillary network monitors activity and controls blood flow
27.03.2017 | Larner College of Medicine at the University of Vermont
Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
27.03.2017 | Health and Medicine
27.03.2017 | Life Sciences
27.03.2017 | Earth Sciences